ArticleiGIE : innovation, investigation and insights2025
Safety and efficacy of endoscopic sleeve gastroplasty after liver transplantation.
Article in iGIE : innovation, investigation and insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Endobariatric Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.Biomedicines · 2026Review
- Endoscopic sleeve gastrectomyWorld journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Metabolic syndrome after liver transplantation: A silent threat to long-term success.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Obesity after liver transplantation (LT) can compromise patient outcomes. We report safety and efficacy data on endoscopic sleeve gastroplasty (ESG) after LT. Methods: This is a retrospective case series of patients who underwent ESG after LT. Results: All 5 patients underwent ESG at a median 47.3 months (interquartile range [IQR], 34.4-67.4 months) after LT. Patients were predominantly male (4/5, 80%) with median age 61 years (IQR, 51-61 years) and preoperative body mass index 38.8 kg/m Conclusions: Our data support the use of ESG after LT, although more data are needed to validate our findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.